Information in relation to COVID-19

GOTHENBURG, Sweden, April 2, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), has since the outbreak and spread of COVID-19 followed the development and effects closely. The company has taken proactive measures to ensure continuity of the global Phase 3 AGENT study, which will continue to enrol patients in line with regulatory guidelines and site capabilities.

The spread of the COVID-19 pandemic is effecting societies and companies all over the world and will have a significant impact on the global healthcare system. Many hospitals, regions and countries are updating their guidelines and Isofol is taking necessary steps to fully comply with new guidance. Isofol’s top priority is to ensure the safety of patients, healthcare professionals, employees and suppliers involved in the ongoing AGENT study. The company is also working closely with local health authorities to enable study continuity on a global basis.

The AGENT study will enrol a total of 440 patients with metastatic colorectal cancer, and the company has already enrolled 265 patients to date. During March, 27 new patients were enrolled in the study which is in line with the enrolment plan.

The effects of COVID-19 remain difficult to fully monitor and if there will be any impact on the patient recruitment pace is at this stage too early to predict.

For further information, please contact

Isofol Medical AB (publ)
Jarl Ulf Jungnelius, M.D., Chief Executive Officer
E-mail: jungnelius@isofolmedical.com
Phone: +46 (0) 709 16 89 55

Certified Adviser
FNCA Sweden AB
E-mail: info@fnca.se
Phone: +46 (0) 8 528 003 99

The information was submitted for publication, through the agency of the contact person set out above, at 08.00 CET on April 2, 2020.

About arfolitixorin

Arfolitixorin is Isofol’s proprietary drug candidate being developed to increase the efficacy of standard of care chemotherapy for advanced colorectal cancer. The drug candidate is currently being studied in a global Phase 3 study, AGENT. As the key active metabolite of the widely used folate-based drugs, arfolitixorin can potentially benefit all patients with advanced colorectal cancer, as it does not require complicated metabolic activation to become effective.

About Isofol Medical AB (publ)

Isofol Medical AB (publ) is a clinical stage biotech company developing arfolitixorin to improve the efficacy of standard of care chemotherapy for advanced colorectal cancer by increasing tumor response and progression free survival. Isofol holds a worldwide exclusive license agreement with Merck KGaA, Darmstadt, Germany to develop and commercialize arfolitixorin for oncology indications. Isofol Medical AB (publ) is traded on the Nasdaq First North Premier Growht Market. Certified Adviser is FNCA Sweden AB.

www.isofolmedical.com

For further information, please contact

Document